POSIFIT SAS was founded in Nancy in 2007 during the establishment of the NANCYCLOTEP GIE.

It is the industrial valorization operator for NANCYCLOTEP.

Since the beginning of 2021, POSIFIT has become a pharmaceutical establishment and obtained authorization from ANSM (French National Agency for Medicines and Health Products Safety) to produce clinical radiopharmaceuticals at its Strasbourg site.

POSIFIT's objective, alongside NANCYCLOTEP, is to become a key player in France and Europe in the production of radiopharmaceuticals for both diagnostic and therapeutic purposes in clinical trials.

We offer our expertise to various stakeholders in the radiopharmaceutical field for the development and production of radiopharmaceuticals.

In the first quarter of 2024, POSIFIT S.A.S. will open a second pharmaceutical establishment in Nancy, equipped with a cyclotron for the production of Fluorine-18, Carbon-11, Gallium-68, and Nitrogen-13.